{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:56:46Z","timestamp":1791053806064,"version":"4.1.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cutaneous T-cell lymphoma (CTCL) is a lymphoproliferative skin disease with limited therapeutic options. Ten CTCL patients were treated with once-weekly intranodal injection of 1 \u00d7 106 mature monocyte-derived dendritic cells (DCs) pulsed with 100 \u03bcg\/mL tumor lysate protein equivalent and keyhole limpet hemocyanin (50 \u03bcg\/mL). Tumor-specific delayed-type hypersensitivity (DTH) reactions developed in 8 of 8 patients challenged with tumor-lysate-pulsed DCs and in 3 of 8 patients challenged with tumor lysate alone. Three of 5 patients showed significant tumor-lysate-specific increases of in vitro peripheral blood lymphocyte proliferation coinciding with increased interferon-\u03b1 (IFN-\u03b1) production. Five of 10 (50%) patients had objective responses. Four patients had partial responses (PRs). Two are still in PR, and the other 2 patients had a mean PR duration of 10.5 months. One patient had a complete response (CR) for 19 months that is ongoing. The remaining 5 patients had progressive disease. In the 5 responder patients, 6.8 \u00b1 1.4 vaccinations were necessary to induce an objective clinical response. Response was associated with low tumor burden. Continuation of vaccinations with new tumor lysate derived from progressive lesions reinduced treatment responses in 2 patients in PR. Selected patients had massive infiltration of CD8+ and TIA+ cytotoxic T cells at the site of regressing lesions and molecular remission after therapy. Intranodal injection of autologous tumor-lysate-pulsed DCs is well-tolerated and achieves immunologic and objective clinical responses in selected CTCL patients. (Blood. 2003;102:2338-2344)<\/jats:p>","DOI":"10.1182\/blood-2002-08-2455","type":"journal-article","created":{"date-parts":[[2003,4,29]],"date-time":"2003-04-29T00:14:21Z","timestamp":1051575261000},"page":"2338-2344","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":115,"title":["Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate\u2013pulsed dendritic cells"],"prefix":"10.1182","volume":"102","author":[{"given":"Tanja","family":"Maier","sequence":"first","affiliation":[{"name":"From the Department of Dermatology and the Institute of Diagnostic Radiology, University Hospital Zurich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Tun-Kyi","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and the Institute of Diagnostic Radiology, University Hospital Zurich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatoli","family":"Tassis","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and the Institute of Diagnostic Radiology, University Hospital Zurich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Peter","family":"Jungius","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and the Institute of Diagnostic Radiology, University Hospital Zurich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gu\u0308nter","family":"Burg","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and the Institute of Diagnostic Radiology, University Hospital Zurich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and the Institute of Diagnostic Radiology, University Hospital Zurich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank O.","family":"Nestle","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and the Institute of Diagnostic Radiology, University Hospital Zurich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021222113883700_REF1","doi-asserted-by":"crossref","unstructured":"Burg G, Braun-Falco O. Cutaneous lymphomas, pseudolymphomas and related disorders. Berlin, Germany: Springer-Verlag; 1983.","DOI":"10.1007\/978-3-662-00888-1"},{"key":"2020021222113883700_REF2","doi-asserted-by":"crossref","unstructured":"Edelson RL. Cutaneous T cell lymphoma: mycosis fungoides, Sezary syndrome, and other variants. J Am Acad Dermatol. 1980;2: 89-106.","DOI":"10.1016\/S0190-9622(80)80385-9"},{"key":"2020021222113883700_REF3","doi-asserted-by":"crossref","unstructured":"Jahn S, Asadullah K, Walden P, Sterry W. Cutaneous malignant lymphomas. Immunol Today. 1998;19: 100-103.","DOI":"10.1016\/S0167-5699(98)80004-2"},{"key":"2020021222113883700_REF4","doi-asserted-by":"crossref","unstructured":"Burg G, Dummer R, Dommann S, Nestle F, Nickoloff B. Pathology of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995;9: 961-995.","DOI":"10.1016\/S0889-8588(18)30053-4"},{"key":"2020021222113883700_REF5","unstructured":"Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997;90: 354-371."},{"key":"2020021222113883700_REF6","doi-asserted-by":"crossref","unstructured":"Jaffe ES, Sander CA, Flaig MJ. Cutaneous lymphomas: a proposal for a unified approach to classification using the R.E.A.L.\/WHO Classification. Ann Oncol. 2000;11(suppl 1): 17-21.","DOI":"10.1093\/annonc\/11.suppl_1.S17"},{"key":"2020021222113883700_REF7","unstructured":"Nestle FO, Haffner AC, Schmid MH, Dummer R, Burg G. Moderne Therapiekonzepte bei kutanen T-Zell-Lymphomen [Current therapy concepts in cutaneous T-cell lymphomas]. Schweiz Med Wochenschr. 1997;127: 311-320."},{"key":"2020021222113883700_REF8","unstructured":"Stadler R, Otte HG, Luger T, et al. Prospective randomized multicenter clinical trial on the use of interferon-2\u03b1 plus acitretin versus interferon-2\u03b1 plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood. 1998;92: 3578-3581."},{"key":"2020021222113883700_REF9","doi-asserted-by":"crossref","unstructured":"Rook AH, Wood GS, Yoo EK, et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood. 1999;94: 902-908.","DOI":"10.1182\/blood.V94.3.902.415k23_902_908"},{"key":"2020021222113883700_REF10","doi-asserted-by":"crossref","unstructured":"Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001;19: 376-388.","DOI":"10.1200\/JCO.2001.19.2.376"},{"key":"2020021222113883700_REF11","doi-asserted-by":"crossref","unstructured":"Linnemann T, Tumenjargal S, Gellrich S, et al. Mimotopes for tumor-specific T lymphocytes in human cancer determined with combinatorial peptide libraries. Eur J Immunol. 2001;31: 156-165.","DOI":"10.1002\/1521-4141(200101)31:1<156::AID-IMMU156>3.0.CO;2-P"},{"key":"2020021222113883700_REF12","doi-asserted-by":"crossref","unstructured":"Edelson RL. Cutaneous T cell lymphoma: the helping hand of dendritic cells. Ann N Y Acad Sci. 2001;941: 1-11.","DOI":"10.1111\/j.1749-6632.2001.tb03705.x"},{"key":"2020021222113883700_REF13","doi-asserted-by":"crossref","unstructured":"Berger CL, Xu AL, Hanlon D, et al. Induction of human tumor-loaded dendritic cells. Int J Cancer. 2001;91: 438-447.","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1073>3.0.CO;2-R"},{"key":"2020021222113883700_REF14","doi-asserted-by":"crossref","unstructured":"Berger CL, Hanlon D, Kanada D, et al. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood. 2002;99: 2929-2939.","DOI":"10.1182\/blood.V99.8.2929"},{"key":"2020021222113883700_REF15","doi-asserted-by":"crossref","unstructured":"Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate pulsed dendritic cells. Nat Med. 1998;4: 328-332.","DOI":"10.1038\/nm0398-328"},{"key":"2020021222113883700_REF16","doi-asserted-by":"crossref","unstructured":"Nestle FO, Banchereau J, Hart D. Dendritic cells: on the move from bench to bedside. Nat Med. 2001;7: 761-765.","DOI":"10.1038\/89863"},{"key":"2020021222113883700_REF17","doi-asserted-by":"crossref","unstructured":"Schmid MH, Bird P, Dummer R, Kempf W, Burg G. Tumor burden index as a prognostic tool for cutaneous T-cell lymphoma: a new concept. Arch Dermatol. 1999;135: 1204-1208.","DOI":"10.1001\/archderm.135.10.1204"},{"key":"2020021222113883700_REF18","doi-asserted-by":"crossref","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47: 207-214.","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"2020021222113883700_REF19","doi-asserted-by":"crossref","unstructured":"Jonuleit H, Kuhn U, Muller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997;27: 3135-3142.","DOI":"10.1002\/eji.1830271209"},{"key":"2020021222113883700_REF20","unstructured":"Nestle FO, Burg G, Fa\u0308h J, Wrone-Smith T, Nickoloff BJ. Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am J Pathol. 1997;150: 641-651."},{"key":"2020021222113883700_REF21","doi-asserted-by":"crossref","unstructured":"Meyer JC, Hassam S, Dummer R, et al. A realistic approach to the sensitivity of PCR-DGGE and its application as a sensitive tool for the detection of clonality in cutaneous T-cell proliferations. Exp Dermatol. 1997;6: 122-127.","DOI":"10.1111\/j.1600-0625.1997.tb00158.x"},{"key":"2020021222113883700_REF22","doi-asserted-by":"crossref","unstructured":"Romero P, Cerottini J-C, Waanders GA. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. Mol Med Today. 1998;4: 305-312.","DOI":"10.1016\/S1357-4310(98)01280-5"},{"key":"2020021222113883700_REF23","doi-asserted-by":"crossref","unstructured":"Bagot M, Echchakir H, Mami Chouaib F, et al. Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma. Blood. 1998;91: 4331-4341.","DOI":"10.1182\/blood.V91.11.4331"},{"key":"2020021222113883700_REF24","doi-asserted-by":"crossref","unstructured":"Rook AH, Yoo EK, Grossman DJ, Kao DM, Fox FE, Niu Z. Use of biological response modifiers in the treatment of cutaneous T-cell lymphoma. Curr Opin Oncol. 1998;10: 170-174.","DOI":"10.1097\/00001622-199803000-00015"},{"key":"2020021222113883700_REF25","doi-asserted-by":"crossref","unstructured":"Haffner AC, Tassis A, Zepter K, et al. Expression of cancer\/testis antigens in cutaneous T cell lymphomas. Int J Cancer. 2002;97: 668-670.","DOI":"10.1002\/ijc.1643"},{"key":"2020021222113883700_REF26","doi-asserted-by":"crossref","unstructured":"Eichmuller S, Usener D, Dummer R, Stein A, Thiel D, Schadendorf D. Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci U S A. 2001;98: 629-634.","DOI":"10.1073\/pnas.98.2.629"},{"key":"2020021222113883700_REF27","doi-asserted-by":"crossref","unstructured":"Wilson LD, Jones GW, Kim D, et al. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. J Am Acad Dermatol. 2000;43: 54-60.","DOI":"10.1067\/mjd.2000.105510"},{"key":"2020021222113883700_REF28","doi-asserted-by":"crossref","unstructured":"Muche JM, Gellrich S, Sterry W. Treatment of cutaneous T-cell lymphomas. Semin Cutan Med Surg. 2000;19: 142-148.","DOI":"10.1053\/sder.2000.8328"},{"key":"2020021222113883700_REF29","doi-asserted-by":"crossref","unstructured":"Foss FM. An oncologist's approach to therapy for cutaneous T-cell lymphoma. Clin Lymphoma. 2000;1(suppl 1): S9-S14.","DOI":"10.3816\/CLM.2000.s.002"},{"key":"2020021222113883700_REF30","doi-asserted-by":"crossref","unstructured":"Duvic M. Treatment of cutaneous T-cell lymphoma from a dermatologist's perspective. Clin Lymphoma. 2000;(suppl 1): S15-S20.","DOI":"10.3816\/CLM.2000.s.003"},{"key":"2020021222113883700_REF31","doi-asserted-by":"crossref","unstructured":"Kurzrock R, Pilat S, Duvic M. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol. 1999;17: 3117-3121.","DOI":"10.1200\/JCO.1999.17.10.3117"},{"key":"2020021222113883700_REF32","doi-asserted-by":"crossref","unstructured":"Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001;19: 2456-2471.","DOI":"10.1200\/JCO.2001.19.9.2456"},{"key":"2020021222113883700_REF33","doi-asserted-by":"crossref","unstructured":"Rook AH, Zaki MH, Wysocka M, et al. The role for interleukin-12 therapy of cutaneous T cell lymphoma. Ann N Y Acad Sci. 2001;941: 177-184.","DOI":"10.1111\/j.1749-6632.2001.tb03721.x"},{"key":"2020021222113883700_REF34","doi-asserted-by":"crossref","unstructured":"Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2: 52-58.","DOI":"10.1038\/nm0196-52"},{"key":"2020021222113883700_REF35","doi-asserted-by":"crossref","unstructured":"Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002;99: 1517-1526.","DOI":"10.1182\/blood.V99.5.1517"},{"key":"2020021222113883700_REF36","doi-asserted-by":"crossref","unstructured":"Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma\u2014a feasibility study. Blood. 1999;93: 2411-2419.","DOI":"10.1182\/blood.V93.7.2411"},{"key":"2020021222113883700_REF37","doi-asserted-by":"crossref","unstructured":"Lim SH, Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer. 1999;83: 215-222.","DOI":"10.1002\/(SICI)1097-0215(19991008)83:2<215::AID-IJC12>3.0.CO;2-Q"},{"key":"2020021222113883700_REF38","doi-asserted-by":"crossref","unstructured":"Titzer S, Christensen O, Manzke O, et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol. 2000;108: 805-816.","DOI":"10.1046\/j.1365-2141.2000.01958.x"},{"key":"2020021222113883700_REF39","doi-asserted-by":"crossref","unstructured":"Cull G, Durrant L, Stainer C, Haynes A, Russell N. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Br J Haematol. 1999;107: 648-655.","DOI":"10.1046\/j.1365-2141.1999.01735.x"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/7\/2338\/1691720\/h81903002338.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/7\/2338\/1691720\/h81903002338.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T03:14:36Z","timestamp":1581563676000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/102\/7\/2338\/17993\/Vaccination-of-patients-with-cutaneous-Tcell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10,1]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2003,10,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-08-2455","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10,1]]}}}